DR. NYRIA CAROLINA VILLARREAL M.D.
Prescription History 1376869784
Internal Medicine - Infectious Disease in Indianapolis, IN

NPI Status: Active since April 09, 2010

Contact Information

7250 CLEARVISTA DR
SUITE 260
INDIANAPOLIS, IN
ZIP 46256
Phone: (317) 621-1690
Fax: (317) 621-1699

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. NYRIA CAROLINA VILLARREAL M.D., an active Infectious Disease specialist practicing in Indianapolis, IN. Our medical registry currently tracks 25 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 763 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 113 claims alone.


Amoxicillin

Generic Formulation: AmoxicillinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 37.0
Days Supply 1,052
IN State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills39.0
Peer Average Days Supply264
Conservative Utilization

This provider writes prescriptions for this formulation 44.7% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $214.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.20

State Avg Cost Per Claim

$3.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.

Therapeutic Applications

Amoxicillin is used to treat a wide variety of bacterial infections. This medication is a penicillin-type antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. Amoxicillin is also used with other medications to treat stomach/intestinal ulcers caused by the bacteria H. pylori and to prevent the ulcers from returning.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 32
30-Day Fills 38.0
Days Supply 1,044
IN State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.1
Peer Average Days Supply223
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.0% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,523.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$47.62

State Avg Cost Per Claim

$12.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 25.0
Days Supply 646
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills35.7
Peer Average Days Supply279
Conservative Utilization

This provider writes prescriptions for this formulation 38.2% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $499.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.77

State Avg Cost Per Claim

$9.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 113
30-Day Fills 113.0
Days Supply 3,390
IN State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills72.7
Peer Average Days Supply2,180
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.9% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $465,888.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,122.91

State Avg Cost Per Claim

$3,919.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cefdinir

Generic Formulation: CefdinirSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 24.0
Days Supply 597
IN State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.7
Peer Average Days Supply244
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $199.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.27

State Avg Cost Per Claim

$21.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.

Therapeutic Applications

Cefdinir is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 124
IN State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.4
Peer Average Days Supply114
Conservative Utilization

This provider writes prescriptions for this formulation 35.7% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,965.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$164.75

State Avg Cost Per Claim

$48.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Cephalexin

Generic Formulation: CephalexinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 85
30-Day Fills 108.4
Days Supply 2,981
IN State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply393
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 157.6% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,779.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.93

State Avg Cost Per Claim

$8.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 140
IN State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.4
Peer Average Days Supply259
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.73

State Avg Cost Per Claim

$8.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Clindamycin Hcl

Generic Formulation: Clindamycin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 41
30-Day Fills 55.0
Days Supply 1,547
IN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.2
Peer Average Days Supply157
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 86.4% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $778.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.00

State Avg Cost Per Claim

$9.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.

Therapeutic Applications

Clindamycin is used to treat a wide variety of bacterial infections. It is an antibiotic that works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Daptomycin

Generic Formulation: DaptomycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 47
30-Day Fills 47.0
Days Supply 328
IN State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.3
Peer Average Days Supply137
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 80.8% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $44,104.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$938.39

State Avg Cost Per Claim

$1,127.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Therapeutic Applications

This medication is an antibiotic used to treat serious bacterial infections. It works by stopping the growth of bacteria. This medication is not recommended for use in children younger than 12 months due to possible risk of serious side effects.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
IN State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply854
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.9% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,183.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,321.79

State Avg Cost Per Claim

$2,292.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 74
30-Day Fills 84.0
Days Supply 2,305
IN State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply431
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 155.2% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,163.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$56.26

State Avg Cost Per Claim

$23.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Ertapenem

Generic Formulation: Ertapenem SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 178
IN State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply106
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.0% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,033.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$847.46

State Avg Cost Per Claim

$533.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.

Therapeutic Applications

Ertapenem is used to prevent and treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 204
IN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills24.5
Peer Average Days Supply248
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $606.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.66

State Avg Cost Per Claim

$12.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Isentress

Generic Formulation: Raltegravir PotassiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.5
Peer Average Days Supply691
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $22,695.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,063.23

State Avg Cost Per Claim

$1,976.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.

Therapeutic Applications

Raltegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Raltegravir is known as an integrase inhibitor. It blocks the virus from growing and infecting more cells. Raltegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Itraconazole

Generic Formulation: ItraconazoleSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.7
Days Supply 446
IN State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills21.6
Peer Average Days Supply612
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,274.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$151.65

State Avg Cost Per Claim

$291.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.

Therapeutic Applications

Itraconazole is used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.

Lamivudine-Zidovudine

Generic Formulation: Lamivudine/ZidovudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IN State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply510
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,340.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$394.55

State Avg Cost Per Claim

$289.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 2 drugs: lamivudine and zidovudine. It is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Both lamivudine and zidovudine belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Lamivudine/zidovudine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Meropenem

Generic Formulation: MeropenemSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 163
IN State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.2
Peer Average Days Supply74
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,096.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$254.00

State Avg Cost Per Claim

$265.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.

Therapeutic Applications

Meropenem is used to treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.

Prezcobix

Generic Formulation: Darunavir/CobicistatSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
IN State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.1
Peer Average Days Supply781
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $59,347.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,580.33

State Avg Cost Per Claim

$2,484.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: darunavir and cobicistat. Darunavir belongs to a class of drugs known as protease inhibitors. Cobicistat is used to increase (boost) the levels of darunavir. Darunavir/cobicistat is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Rifampin

Generic Formulation: RifampinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 25.0
Days Supply 750
IN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills27.2
Peer Average Days Supply763
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,885.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$81.96

State Avg Cost Per Claim

$60.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Rukobia

Generic Formulation: Fostemsavir TromethamineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
IN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.8
Peer Average Days Supply714
Conservative Utilization

This provider writes prescriptions for this formulation 43.5% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $116,858.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$8,989.10

State Avg Cost Per Claim

$8,870.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Fostemsavir is changed in your body to its active drug form. It works by helping to prevent attachment of and entry of the (HIV-1) virus into healthy cells in your body. Fostemsavir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 41.5
Days Supply 824
IN State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.6
Peer Average Days Supply407
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 44.4% more claims than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $347.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.91

State Avg Cost Per Claim

$6.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Symtuza

Generic Formulation: Darunavir/Cob/Emtri/Tenof AlafSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 510
IN State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.1
Peer Average Days Supply985
Conservative Utilization

This provider writes prescriptions for this formulation 46.9% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $84,939.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,996.42

State Avg Cost Per Claim

$4,709.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: darunavir, cobicistat, emtricitabine, and tenofovir alafenamide. Darunavir is known as a protease inhibitor. Cobicistat helps darunavir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor; both kinds of drugs are often called NRTIs. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Tivicay

Generic Formulation: Dolutegravir SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
IN State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.8
Peer Average Days Supply1,091
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $101,646.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,080.21

State Avg Cost Per Claim

$2,368.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dolutegravir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Dolutegravir belongs to a class of drugs known as integrase inhibitors. It blocks the virus from growing and infecting more cells. Dolutegravir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Vancomycin Hcl

Generic Formulation: Vancomycin HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.9
Days Supply 299
IN State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.2
Peer Average Days Supply217
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,135.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$356.79

State Avg Cost Per Claim

$164.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Therapeutic Applications

Vancomycin is an antibiotic used to treat infections. This form of vancomycin is used to treat a certain intestinal condition (colitis) caused by bacteria. This condition causes diarrhea and stomach/abdominal discomfort or pain. When vancomycin is taken by mouth, it stays in the intestines to stop the growth of certain bacteria that cause these symptoms. This antibiotic treats only bacterial infection in the intestines. It will not work for bacterial infections in any other part of the body or for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. NYRIA CAROLINA VILLARREAL M.D. provides transparency into local medical care patterns within Indianapolis, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.